GenSight Biologics S.A. (OTCMKTS:GSGTF – Get Free Report) shares dropped 25% on Wednesday . The company traded as low as $0.24 and last traded at $0.24. Approximately 4,012 shares changed hands during trading, an increase of 588% from the average daily volume of 583 shares. The stock had previously closed at $0.32.
GenSight Biologics Stock Down 25.0 %
The company’s fifty day simple moving average is $0.32 and its 200-day simple moving average is $0.34.
About GenSight Biologics
GenSight Biologics SA, a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Featured Stories
- Five stocks we like better than GenSight Biologics
- How to Calculate Return on Investment (ROI)
- Constellation Energy: Stock Climbs on Billion-Dollar Contract
- What Does Downgrade Mean in Investing?
- Vistra Stock: Powered for Continued Gains in the New Year
- What is a support level?
- These 3 AI Stocks Are Ready to Lead in 2025
Receive News & Ratings for GenSight Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenSight Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
